ID: ALA2207396

Max Phase: Preclinical

Molecular Formula: C4H9NO2

Molecular Weight: 103.12

Molecule Type: Small molecule

Representations

Synonyms (1): Pyrrolidine-3,4-Diol
Synonyms from Alternative Forms(1):

Canonical SMILES:  O[C@@H]1CNC[C@@H]1O

Standard InChI:  InChI=1S/C4H9NO2/c6-3-1-5-2-4(3)7/h3-7H,1-2H2/t3-,4+

Standard InChI Key:  JCZPOYAMKJFOLA-ZXZARUISSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 103.12

Molecular Weight (Monoisotopic): 103.0633

AlogP: -1.69

#Rotatable Bonds: 0

Polar Surface Area: 52.49

Molecular Species: BASE

HBA: 3

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 3

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.51

CX Basic pKa: 9.86

CX LogP: -1.63

CX LogD: -4.02

Aromatic Rings: 0

Heavy Atoms: 7

QED Weighted: 0.34

Np Likeness Score: 1.21

References

1. Popowycz F, Gerber-Lemaire S, Demange R, Rodriguez-García E, Asenjo AT, Robina I, Vogel P..  (2001)  Derivatives of (2R,3R,4S)-2-aminomethylpyrrolidine-3,4-diol are selective alpha-mannosidase inhibitors.,  11  (18): [PMID:11549453] [10.1016/s0960-894x(01)00477-2]

2. Robina I, Moreno-Vargas AJ, Fernández-Bolaños JG, Fuentes J, Demange R, Vogel P..  (2001)  New leads for selective inhibitors of alpha-L-fucosidases. Synthesis and glycosidase inhibitory activities of [(2R,3S,4R)-3,4-dihydroxypyrrolidin-2-yl]furan derivatives.,  11  (18): [PMID:11549468] [10.1016/s0960-894x(01)00497-8]

3. Moorthy NS, Brás NF, Ramos MJ, Fernandes PA..  (2012)  Virtual screening and QSAR study of some pyrrolidine derivatives as α-mannosidase inhibitors for binding feature analysis.,  20  (24): [PMID:23151473] [10.1016/j.bmc.2012.10.011]

Source

Source(1):

• Scientific Literature